Cipher’s leadership has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products.

Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.

Craig Mull

Interim Chief Executive Officer

Craig Mull is currently the managing director of 1207407 Ontario Limited and is responsible for overseeing a variety of its investments which includes the entity’s interest in the Corporation. Mr. Mull is also the founder and Chief Executive Officer of Typhon Group Ltd, a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area. He served as Director of Corporate Development, Vice President and Chief Operating Officer of CML from 1989 to 2004 where he was instrumental in the company’s growth. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from less than $20 million in annualized revenue to over $235 million. Prior to joining CML, Mr. Mull held the role of Sales and Marketing Manager at Baxter Corporation. Mr. Mull received an HBA from Ivey Business School at the University of Western Ontario.

Diane Gajewczyk

Vice President, Scientific & Medical Affairs

Dr. Diane Gajewczyk, has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.

Prior to joining Cipher, Dr. Gajewczyk held the position of Senior Director, Medical Affairs with Galderma Canada, where she was responsible for medical and regulatory strategy and was involved in the registration and launch of a number of products. Previously, Dr. Gajewczyk spent almost ten years at Biovail Corporation in several senior positions, including Senior Director, Medical & Scientific Affairs, leading the scientific aspects of corporate development transactions. Prior to focusing on medical and scientific affairs, she spent 12 years in pharmaceutical R&D at Sanofi Pasteur where she developed numerous patents and conducted IND-enabling studies for novel therapeutics.

Dr. Gajewczyk obtained her PhD in Microbiology and Immunology from the University of Toronto, as well as her MBA from the Richard Ivey School of Business at Western University.